<DOC>
	<DOC>NCT01065454</DOC>
	<brief_summary>The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction</brief_summary>
	<brief_title>A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction</brief_title>
	<detailed_description>Pharmacokinetics parameters were regarded as exploratory parameters. Adverse event data will be covered in Adverse events section.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<criteria>Male and female patients with symptomatic pulmonary hypertension due to left ventricular systolic dysfunction despite optimized heart failure therapy Types of pulmonary hypertension other than group 2.1 of Dana Point Classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Left ventricular dysfunction</keyword>
</DOC>